Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a JPMorgan ...

Arizona AG urges eligible consumers to claim compensation from a $39.1 million Apotex settlement over inflated generic drug ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

West Pharmaceutical Servs's WST short percent of float has risen 12.9% since its last report. The company recently reported ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Though the first chapter of Adult Swim’s Common Side Effects animated series is about to wrap up this Sunday, the story isn’t ...

Harrow, Inc. offers speculative gains from $20s to $30s, with Q4 growth, bullish 2025 revenue guidance, and long-term growth ...

Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 61.33%, which has investors questioning if this is right time to buy.

The new recipients of 23andMe’s data would not necessarily have to offer consumers the ability to opt out once they take possession of it. And it remains unclear which (or how many) hands the data ...